Here Is A New Book To Warns Us About The Escalating Global Tensions and the Risks of a Nuclear Conflict

Here Is A New Book To Warns Us About The Escalating Global Tensions and the Risks of a Nuclear Conflict

We might be unaware, but the world is at a crossroads of destruction. With rising geopolitical tensions and the potential for a catastrophic global war, there soon comes a time when we might be facing a nuclear war more devastating than all the previous.

In light of this, in his latest book, Ramifications of a Possible New World War: A Layman’s Assessment, economist and strategic thinker Godfrey Simon David Bvute provides a thought-provoking analysis of the current international security landscape. By presenting a strong case for the potential of nuclear war, this book urges us to consider the real possibility of nuclear escalation and provides plausible measures to stop it before time runs out.

By exploring the ongoing conflict in Ukraine, highlighting its broader geopolitical ramifications and the increasing involvement of world powers, this book warns that without meaningful diplomatic efforts, the world could see an unprecedented conflict that may involve nuclear weapons. The book also offers a historical perspective on military confrontations and their economic consequences, drawing lessons from past conflicts to advocate for peace and diplomacy.

“This book is not just about war; it is about survival,” says Bvute. “My hope is to raise awareness about the dangers of escalation and encourage dialogue toward a peaceful resolution before it is too late.”

In the end, with the potential for further nuclear posturing from global powers, Ramifications of a Possible New World War serves as a wake-up call for policymakers, academics, and the general public to stop the possibility of a nuclear war. Bvute argues that global cooperation and multilateral diplomacy are the only viable paths to preventing a catastrophic conflict.

Available now, the book can be purchased online and in select bookstores.

About the author:

Godfrey Simon David Bvute was born and raised in the rural Honde Valley of Manicaland Province, Zimbabwe, near the Mozambique border. His early education was disrupted by the Rhodesian civil war, forcing him to relocate to Salisbury (now Harare) as an Internally Displaced Person (IDP), where he completed his secondary education. He later earned a degree in Economics from the University of Zimbabwe in 1985, followed by postgraduate studies in Economics and Strategic Management from the Universities of South Africa and Derby (UK). Bvute’s career spanned roles in insurance, government tax assessment, and 20 years in commercial and development banking, where he rose to General Manager. He later led the African Coalition on Debt and Development (AFRODAD) before serving 11 years with the United Nations in Zimbabwe and Namibia, retiring at 58. His journey reflects resilience, leadership, and a deep understanding of economic and social development.

Book Name: Ramifications of a Possible New World War: A Layman’s Assessment

Author Name: Godfrey Simon David Bvute

ISBN Number: 1779341008

Ebook Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Shrewd Book Marketing
Email: Send Email
Phone: +1-323-342-5903
Address:10880 Wilshire Blvd 13th floor
City: Los Angeles
State: CA 90024
Country: United States
Website: https://shrewdbookmarketing.com

Abdominal Aortic Stent Grafts Market to Witness Upsurge in Growth by 2030, Assesses DelveInsight

DelveInsight’s Abdominal Aortic Stent Market Insights Report provides the current and forecast market analysis, individual leading Abdominal Aortic Stent Companies market shares, challenges, Abdominal Aortic Stent Market Drivers, barriers, trends, and key market Abdominal Aortic Stent Companies in the market.

To read more about the latest highlights related to the Abdominal Aortic Stent Market, get a snapshot of the key highlights entailed in the Market Report @ Abdominal Aortic Stent Grafts Pipeline Product Market

Key Takeaways from the Abdominal Aortic Stent Market Report

  • The Global Abdominal Aortic Stent Grafts Market is estimated to grow at a CAGR of 4.31% during the forecast period from 2024 to 2030.
  • The Abdominal Aortic Stent Grafts Market is experiencing significant growth, driven by the increasing prevalence of abdominal aortic aneurysms (AAA) and the rising demand for minimally invasive surgical procedures.
  • The leading Abdominal Stent Graft Companies such as Endologix LLC., Medtronic, Terumo Aortic, MicroPort Scientific Corporation, Cook Medical, Cordis, JOTEC GmbH, W. L. Gore & Associates, Inc., Lombard Medical, Lifetech Scientific, SB-Kawasumi Laboratories, Inc., Endospan, Cardinal Health, Artivion Inc., Latecba SA, Nectero Medical, Cardiatis SA, Hangzhou Endonom Medtech Co., Ltd., and others.

To know more about why North America is leading the market growth in the Abdominal Aortic Stent Grafts Market, get a snapshot @ Abdominal Aortic Stent Grafts Market Outlook

Abdominal Aortic Stent Grafts Market Dynamics

According to the estimates of DelveInsight the total diagnosed prevalent population of abdominal aortic aneurysm (AAA) in 7MM was estimated to be 1,641,380 cases in 2021. This anticipated surge in AAA cases is likely to drive the demand for abdominal stent-grafts, as they are essential medical devices used for treating abdominal aortic aneurysms thereby boosting the future market of the abdominal stent graft.

Abdominal Stent Graft Market Segment Analysis

Abdominal Stent Graft Market by Material Type (Metal and Polymer), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). In the product segment of the abdominal stent graft market, the metal abdominal stent graft is estimated to have a significant revenue share in the abdominal stent graft market in 2023. This can be attributed to the various advantages and applications provided by the metal abdominal stent graft. Metal abdominal stent grafts offer advantages over polymer ones due to their greater durability, flexibility, and radial force. Metal stents provide better support for the vessel wall, reducing the risk of migration and endoleaks. Additionally, metal stents can be more easily repositioned during deployment and offer improved visibility under imaging, facilitating precise placement.

Get a sneak peek at the Abdominal Aortic Stent Grafts Market Dynamics @ Abdominal Aortic Stent Grafts Product Market Outlook

Abdominal Aortic Stent Grafts Companies

Endologix LLC., Medtronic, Terumo Aortic, MicroPort Scientific Corporation, Cook Medical, Cordis, JOTEC GmbH, W. L. Gore & Associates, Inc., Lombard Medical, Lifetech Scientific, SB-Kawasumi Laboratories, Inc., Endospan, Cardinal Health, Artivion Inc., Latecba SA, Nectero Medical, Cardiatis SA, Hangzhou Endonom Medtech Co., Ltd., and others.

Global Abdominal Stent Graft Market Drivers

The demand for abdominal stent grafts is primarily being boosted by the growing prevalence of abdominal aortic aneurysms and other related issues such as atherosclerosis. Furthermore, the market for abdominal stent grafts is boosted by the rising prevalence of cardiac disease due to smoking, obesity, and high blood pressure as these complications are significant risk factors for the development and progression of abdominal aortic aneurysms. Additionally, the abdominal stent graft market is anticipated to grow on account of increasing number of product approvals, and product launches.

Which MedTech key players in the Abdominal Aortic Stent Grafts Market are set to emerge as the trendsetter explore @ Abdominal Aortic Stent Grafts Companies

Scope of the Abdominal Aortic Stent Grafts Market Report

  • Coverage- Global
  • Abdominal Aortic Stent Grafts Companies- Endologix LLC., Medtronic, Terumo Aortic, MicroPort Scientific Corporation, Cook Medical, Cordis, JOTEC GmbH, W. L. Gore & Associates, Inc., Lombard Medical, Lifetech Scientific, SB-Kawasumi Laboratories, Inc., Endospan, Cardinal Health, Artivion Inc., Latecba SA, Nectero Medical, Cardiatis SA, Hangzhou Endonom Medtech Co., Ltd., and others.
  • Abdominal Aortic Stent Grafts Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World

Interested in knowing the Abdominal Aortic Stent Grafts Market by 2030? Click to get a snapshot of the Abdominal Aortic Stent Grafts Market Trends

Table of Contents

1. Abdominal Stent Graft Market Report Introduction

2. Abdominal Stent Graft Market Executive Summary

3. Competitive Landscape

4. Regulatory Analysis

5. Abdominal Stent Graft Market Key Factors Analysis

6. Abdominal Stent Graft Market Porter’s Five Forces Analysis

7. Abdominal Stent Graft Market Assessment

8. Abdominal Stent Graft Market Company and Product Profiles

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/abdominal-stent-graft-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Abdominal Aortic Stent Grafts Market to Witness Upsurge in Growth by 2030, Assesses DelveInsight

Prurigo Nodularis Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Prurigo Nodularis Pipeline Insights 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prurigo Nodularis pipeline landscape. It covers the Prurigo Nodularis Marketed and Pipeline Drugs profiles, including clinical and nonclinical stage products. It also covers the Prurigo Nodularis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Prurigo Nodularis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Prurigo Nodularis Pipeline Outlook

Key Takeaways from the Prurigo Nodularis Marketed and Pipeline Drugs Report

  • In May 2025, Incyte Corporation announced a study to evaluate the effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
  • In May 2025, Amgen conducted a phase 3 study to assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects with Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies.
  • DelveInsight’s Prurigo Nodularis Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Prurigo Nodularis treatment.
  • The leading Prurigo Nodularis Companies such as Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho, and others.
  • Promising Prurigo Nodularis Pipeline Therapies such as Nalbuphine HCl ER, Povorcitinib, Upadacitinib, Ruxolitinib Cream, INCB054707, Barzolvolimab, Nemolizumab and others.

Stay ahead with the most recent pipeline outlook for Prurigo Nodularis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Prurigo Nodularis Treatment Drugs

Prurigo Nodularis Emerging Drugs Profile

  • Nemolizumab: Chugai/Galderma

Nemolizumab was discovered by Chugai, and uses Chugai’s proprietary antibody engineering technology ACT-Ig, which can extend the biological half-life of antibodies in blood. IL-31 has been identified as a pruritogenic cytokine, and reported to be associated with pruritus in many diseases including atopic dermatitis and hemodialysis. Nemolizumab is designed to inhibit the activities of IL-31 by competitively blocking binding with its receptor. It is currently in phase III stage of development.

  • Nalbuphine ER: Trevi Therapeutics

Trevi is developing nalbuphine ER in a range of indications for which patients have few treatment options. With its dual mechanism of action, acting as both an antagonist (blocker) to the mu opioid receptor and as an agonist (activator) to the kappa opioid receptor, Nalbuphine ER has the potential to significantly improve the quality of life of patients suffering from serious neurologically mediated conditions by targeting the central and peripheral nervous systems. It is currently in phase III stage of development.

  • Vixarelimab: Kiniksa Pharmaceuticals

Vixarelimab is Monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMRβ). Vixarelimab inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key cytokines implicated in inflammation, pruritus, and fibrosis. It is currently in phase II stage of development.

The Prurigo Nodularis Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Prurigo Nodularis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prurigo Nodularis Treatment.
  • Prurigo Nodularis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Prurigo Nodularis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement,s and financing details for future advancement of the Prurigo Nodularis market

Explore groundbreaking therapies and clinical trials in the Prurigo Nodularis Pipeline. Access DelveInsight’s detailed report now! @ New Prurigo Nodularis Drugs

Prurigo Nodularis Companies

Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others.

Prurigo Nodularis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

Prurigo Nodularis Products have been categorized under various Molecule types such as

  • Gene therapies
  • Small molecule
  • Vaccines
  • Polymers
  • Peptides
  • Monoclonal antibodies
  • Product Type

Unveil the future of Prurigo Nodularis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Prurigo Nodularis Market Drivers and Barriers

Scope of the Prurigo Nodularis Pipeline Report

  • Coverage- Global
  • Prurigo Nodularis Companies- Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others.
  • Promising Prurigo Nodularis Pipeline Therapies- Nalbuphine HCl ER, Povorcitinib, Upadacitinib, Ruxolitinib Cream, INCB054707, Barzolvolimab, Nemolizumab and others.
  • Prurigo Nodularis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Prurigo Nodularis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Prurigo Nodularis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Prurigo Nodularis Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Prurigo Nodularis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Prurigo Nodularis – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Prurigo Nodularis Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Nemolizumab: Chugai/Galderma
  11. Nalbuphine ER: Trevi Therapeutics
  12. Mid Stage Products (Phase II)
  13. Vixarelimab: Kiniksa Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Pre-clinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Inactive Products
  21. Prurigo Nodularis Key Companies
  22. Prurigo Nodularis Key Products
  23. Prurigo Nodularis- Unmet Needs
  24. Prurigo Nodularis- Market Drivers and Barriers
  25. Prurigo Nodularis- Future Perspectives and Conclusion
  26. Prurigo Nodularis Analyst Views
  27. Prurigo Nodularis Key Companies
  28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/prurigo-nodularis-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prurigo Nodularis Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Kunlun 4 Pro Mineral Alkaline Water Purifier, a New driver to fuel Viomi’s Growth

Guangzhou, China – Viomi Technology (NASDAQ: VIOT) officially launched its latest innovation, the Kunlun 4 Pro Mineral Alkaline Water Purifier, at a press conference held today. Leveraging AI technology to replicate the natural formation of mineral water, the Kunlun 4 Pro aims to advance household drinking water from the “pure water era” into the “Pure mineral water era”, directly addressing consumers’ increasing demand for healthier hydration.

人们在看台上的人和观众

中度可信度描述已自动生成

Notably, following its 2024 corporate restructuring to focus on water purification, Viomi achieved a turnaround and returned to growth. Full-year revenue increased 29.3% year-over-year to RMB 2.1 billion. The water purification segment has emerged as the core growth engine, achieving 58.2% year-over-year growth in the second half and 39% for the full year. These results not only reflect the early success of Viomi’s strategic focus on water purification business, but also highlight the strong growth potential of the category. The launch of Kunlun 4 Pro is expected to inject further long-term momentum into Viomi’s performance.

图形用户界面, 网站

描述已自动生成

Surging Demand for Mineral Water Redefines Healthy Drinking

Driven by rising health awareness, mineral-rich drinking water is becoming increasingly favored by consumers. Mineral water purifiers, in turn, are benefiting from this trend. According to consumer research, over 55% of respondents express an intent to purchase mineral water purifiers.

To address this demand, Viomi introduced the Kunlun 4 Pro as a next-generation household solution. At the event, Mr. Xiaoping Chen, Founder and CEO of Viomi, noted that the company established the Kunlun Mineral Water Technology Research Center, investing more than RMB 100 million over three years, bringing together a team of over 100 researchers. In collaboration with the China University of Geosciences, Viomi conducted extensive fieldwork across China’s mountain ranges to identify high-quality mineral sources, ultimately selecting natural Kunlun ore as the mineralization core for this new product.

At the heart of the Kunlun 4 Pro is the proprietary Viomi Kunlun Filter, which follows a “purify first, then mineralize” philosophy through a 7+1 stage advanced filtration process, which can effectively remove over 100 harmful substances while enriching the water with six essential minerals (strontium, sodium, magnesium, potassium, calcium, and metasilicate acid). More importantly, the filtered water remains mildly alkaline and very closer to natural mineral waters. This makes it ideal for scenarios like tea brewing, cooking, and infant formula preparation — applications where water quality is especially important..

图形用户界面

中度可信度描述已自动生成

Unlike conventional mineralization cartridges that suffer from early over-release and late-stage depletion, Viomi’s original AI Mineralization Slow-Release System offers a consistent, long-lasting solution. The system integrates three proprietary technologies: NLS (Natural Lava Sintering) Composite Technology, Microporous Mineral Passivation and AI-Powered Mineral Release Algorithm. Mr. Feng Huimin who is the member of China Non-metallic Mineral Products Standardization Technical Committee‌, shared that Kunlun ore contains six essential minerals, with especially high concentrations of strontium and metasilicate acid. The AI-powered process replicates natural mineralization to enable slow, continuous mineral release, bringing filtered water closer in composition to natural mineral water, delivering a high-quality, health-enhancing drinking experience.

The Kunlun 4 Pro also features real-time water quality monitoring, enabled by Viomi’s “AI Algorithm + Smart Sensor” integration. Working in tandem, these components precisely detect changes in water quality. A smart touch-screen faucet visually displays mineral concentration and pH levels in real time. A blue LED strip responds dynamically to drops in mineral content, giving users an intuitive understanding of water conditions. As mineral levels decrease, so does pH, ensuring transparency and user control.

Favorable Policies and Market Recognition Highlight Long-Term Potential

With 2025 marking the first year that water purifiers qualify for national subsidies in China, the policy tailwinds are significant. According to AVC, first-quarter water purifier sales reached RMB 4.2 billion, up 21% YoY, while retail sales of integrated purification units totaled RMB 700 million, up 37% YoY. Products offering health benefits and differentiated features, like mineralization, continue to gain share. The Kunlun 4 Pro aligns precisely with this market trend and is expected to capture a larger share under supportive policies.

At the launch event, Viomi was awarded two industry certifications by leading third-party consultancy S&P Consulting Group: “Inventor of Mineralization Filter Technology”; “National Sales Leader in Filters.” These honors reflect both Viomi’s leadership in R&D and its strong brand recognition in the market.

To further enhance competitiveness, Viomi has invested RMB 1 billion to build a Water Purifier Gigafactory, which is now fully operational. The facility boasts an annual production capacity of 5 million units and 30 million filter cartridges, leveraging intelligent automation across procurement, assembly, and quality control. This large-scale manufacturing reduces costs while ensuring consistent product quality.

蓝色的飞机

低可信度描述已自动生成

In terms of patent technology reserves, Viomi has established deep intellectual property barriers. As of its latest financial reports, the company holds nearly 1,800 global patent applications, with invention patents accounting for over 30%. Core technologies include the AI slow-release algorithm and dual-RO reverse osmosis systems. These foundational technologies underpin the Kunlun 4 Pro and support future product upgrades and global market expansion.

Looking ahead, CEO Xiaoping Chen emphasized Viomi’s long-term vision: “Over the next 10 years, Viomi will increase its investment to deepen AI-driven mineral water purification solutions, lead the transition to a new era of household mineral water and ‌actively expand global water purification business.”

Backed by sustained investment in R&D, precise alignment with favorable policies, and the scale advantages of intelligent manufacturing, Viomi is well-positioned to lead the healthy drinking water sector for years to come. By reshaping the industry landscape and continuously delivering disruptive consumer solutions, Viomi is unlocking new pathways for long-term growth and paving the way for a meaningful revaluation in the capital markets.

Media Contact
Company Name: Viomi Technology Co., Ltd
Contact Person: Xuebo.Li
Email: Send Email
Country: China
Website: https://www.viomi.com/

Adam Blain, Wealth and Retirement Advisor with AAA Life Solutions Interviewed on the Influential Entrepreneurs Podcast, Discussing The Retirement Mountain

Adam Blain Discusses The Retirement Mountain

Listen to the interview on the Business Innovators Radio Network: Interview with Adam Blain, Wealth and Retirement Advisor with AAA Life Solutions -The Retirement Mountain – Business Innovators Radio Network

Adam Blain, is a seasoned retirement advisor from AAA Life Solutions. He delves into the critical topic of retirement planning and the importance of addressing it sooner rather than later. Adam shares his journey into the financial services industry, highlighting his desire to help others and how his career path evolved from aspiring doctor to law enforcement, and ultimately to retirement planning. The conversation emphasizes the significance of not just growing financial accounts but also focusing on how to effectively live off savings during retirement.

Retirement is often seen as the culmination of years of hard work and savings, a time when individuals can finally enjoy the fruits of their labor. However, as Adam Blain emphasizes in the podcast episode, retirement is not solely about accumulating wealth; it also requires a strategic plan for distributing that wealth to ensure it lasts throughout retirement. This process can be likened to safely descending a mountain after a long climb.

Adam uses the analogy of climbing a mountain to illustrate the retirement journey. The ascent represents the accumulation phase, where individuals save and invest to build their retirement nest egg. However, reaching the summit—retirement itself—is only half the journey. The descent, which involves managing and distributing that wealth, is often the more challenging part. Just as mountaineers must navigate their way down carefully to avoid hazards, retirees must have a well-thought-out distribution strategy to ensure their funds last throughout their retirement years.

During the descent, retirees face various risks that can jeopardize their financial security, including:

  • Inflation: The rising cost of living can erode the purchasing power of fixed income sources.
  • Market Volatility: Economic fluctuations can impact investment values, affecting the overall retirement portfolio.
  • Healthcare Costs: Rising medical expenses can significantly drain retirement savings, especially as individuals age.
  • Longevity Risk: With increasing life expectancies, retirees must plan for potentially decades of retirement, which can stretch their savings thin.

Adam points out that many people focus solely on growing their accounts during their working years, neglecting the critical aspect of managing those funds once they retire. This oversight can lead to financial difficulties if retirees do not have a clear plan for their money.

To navigate the descent safely, retirees need a comprehensive distribution strategy. Adam suggests a “bucket” approach to managing retirement funds, which involves segregating money into different categories based on time horizons and risk levels:

  1. Immediate Income Bucket: This short-term bucket is designed for immediate needs and is kept in liquid, conservative investments such as cash or money market accounts. It ensures that retirees have quick access to funds without risking their principal.
  2. Midterm Growth Bucket: This bucket is intended for needs that arise in the next three to ten years. It may involve moderate growth investments that carry a bit more risk but still prioritize capital preservation.
  3. Long-Term Growth Bucket: This bucket is for funds that will not be needed for many years. It can be invested more aggressively to maximize growth potential, helping to combat inflation and ensure that the retiree’s wealth continues to grow over time.

By using this bucket strategy, retirees can create a balanced approach that allows them to manage risks while ensuring they have the necessary income to maintain their desired lifestyle throughout retirement.

Adam also highlights the importance of working with a knowledgeable retirement advisor who can guide clients through the complexities of retirement planning. Many financial professionals focus solely on the accumulation phase, leaving clients unprepared for the distribution phase. A good advisor will help clients understand the implications of their financial decisions, such as the impact of taxes and required minimum distributions (RMDs) on their retirement income.

For example, Adam shares a case of a 70-year-old widow who had accumulated $1.4 million but was living frugally out of fear of running out of money. By analyzing her situation, Adam was able to show her how to spend more comfortably while still planning for taxes and ensuring her financial security. This kind of guidance is crucial for retirees who may not fully understand the long-term implications of their financial choices.

Adam shared: “I guide clients not just to retirement, but through it — with strategies built to handle the descent, not just the climb”

Video Link: https://www.youtube.com/embed/hhnMVXO-GH4

About Adam Blain

Adam Blain is a Wealth and Retirement Advisor based in Germantown, Tennessee, dedicated to helping individuals plan for retirement—whether they’re building their savings or already enjoying retirement life. With over eight years of experience, Adam is Series 65 licensed and also holds life and health insurance licenses. He provides personalized strategies for income planning, investment management, annuities, tax-efficient withdrawals, estate coordination, and Medicare guidance.

Adam serves as a fiduciary under AAA Life Solutions and believes in offering clear, honest advice that’s easy to understand. His approach is faith-driven, educational, and tailored to each client’s goals. Outside of work, Adam is a husband, a proud father of three, and is actively involved in his church and community.

Learn more: https://aaalifesolutions.com/

The opinions expressed by Adam Blain and guests on this show are their own and do not reflect the opinions of this radio station. All Statements and opinions expressed are based upon information considered reliable, although it should not be relied upon as such. Any statements or opinions are subject to change without notice. Investments involve risk and unless otherwise stated are not guaranteed. Past performance cannot be used as an indicator to determine future results. Any strategies mentioned may not be suitable for everyone, information expressed does not take into account your specific situation or objectives and is not intended as recommendations appropriate for you. Before acting on any information mentioned, please consult with a qualified tax or investment advisor to determine if it is suitable for your specific situation. This program is designed to provide accurate and authoritative information with regard to subject covered. Registered Investment Advisors and Investment Advisor Representatives act as fiduciaries for all of our investment management clients. We have an obligation to act in the best interests of our clients and to make full disclosure of any conflicts of interests. Please refer to our firm brochure, the ADV 2A item 4, for additional information. BWA Disclosure: Investment advisory services offered through Brookstone Wealth Advisors, LLC (BWA), a registered investment advisor and an affiliate of Brookstone Capital Management, LLC. BWA and AAA Life Solutions are independent of each other. Insurance products and services are not offered through BWA but are offered and sold through individually licensed and appointed agents.

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com

Exosomes Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Exosomes Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Exosomes Pipeline. Dive into DelveInsight’s comprehensive report today! @ Exosomes Pipeline Outlook

Key Takeaways from the Exosomes Pipeline Report

  • In April 2025, Aegle Therapeutics announced a study, with intra-subject paired- wound control, intended to assess the safety and preliminary efficacy of administering EVs derived from allogeneic MSCs to 10-50 cm2 wounds in RDEB subjects with wounds persisting for at least four weeks.
  • DelveInsight’s Exosomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment.
  • The leading Exosomes Companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others.
  • Promising Exosomes Pipeline Therapies such as Anlotinib, AGLE 102, TISSEEL, and others.

Stay ahead with the most recent pipeline outlook for Exosomes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs

Exosomes Emerging Drugs Profile

  • ExoFlo: Direct Biologics

ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation.

  • EXO-CD24: Nano24

EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage from pathogen-associated molecular patterns (DAMPs and PAMPs) and therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TREx cells. Exosomes displaying murine CD24 (mCD24) were also created.

  • AGLE-102: Aegle Therapeutics

AGLE 102 is an allogeneic-derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material, and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease.

  • Progenza: Cambium Bio

Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose-derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types.

  • EV-101: EV Therapeutics

EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors.

The Exosomes Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
  • Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market

Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline. Access DelveInsight’s detailed report now! @ New Exosomes Drugs

Exosomes Companies

Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others.

Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Exosomes Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Exosomes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Exosomes Market Drivers and Barriers

Scope of the Exosomes Pipeline Report

  • Coverage- Global
  • Exosomes Companies- Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others.
  • Exosomes therapies- Anlotinib, AGLE 102, TISSEEL, and others.
  • Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Exosomes : Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Exosomes – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. CAP-1002: Capricor Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Progenza: Regeneus
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. AGLE 102: Aegle Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Exosomes Key Companies
  21. Exosomes Key Products
  22. Exosomes – Unmet Needs
  23. Exosomes – Market Drivers and Barriers
  24. Exosomes – Future Perspectives and Conclusion
  25. Exosomes Analyst Views
  26. Exosomes Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/exosomes-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exosomes Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Gastrointestinal Stromal Tumor Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Gastrointestinal Stromal Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Gastrointestinal Stromal Tumors Pipeline Outlook

Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Analysis Report

  • In May 2025, Cogent Biosciences Inc. announced a Phase 3 study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 442 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of CGT9486 plus sunitinib to sunitinib alone with patients being randomized in a 1:1 manner.
  • In May 2025, Merck Sharp & Dohme LLC announced a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
  • In May 2025, Deciphera Pharmaceuticals LLC conducted a Phase 1/2 study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
  • DelveInsight’s Gastrointestinal Stromal Tumors Pipeline Analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies.
  • The leading Gastrointestinal Stromal Tumors Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
  • Promising Gastrointestinal Stromal Tumors Therapies such as Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.

Stay ahead with the most recent pipeline outlook for Gastrointestinal Stromal Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Gastrointestinal Stromal Tumors Approved Drugs

Gastrointestinal Stromal Tumors (GIST) Emerging Drugs

  • Famitinib: Jiangsu Hengrui Medicine

Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST).

  • Nilotinib: Novartis

Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors.

  • THE-630: Theseus Pharmaceuticals

THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).

  • DS 6157: Daiichi Sankyo Company

DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in the Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.

The Gastrointestinal Stromal Tumors Pipeline analysis report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumors with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumors Treatment.
  • Gastrointestinal Stromal Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Gastrointestinal Stromal Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumors market.

Explore groundbreaking therapies and clinical trials in the Gastrointestinal Stromal Tumors Pipeline. Access DelveInsight’s detailed report now! @ Gastrointestinal Stromal Tumors Treatment Drugs

Gastrointestinal Stromal Tumors Companies

Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

Gastrointestinal Stromal Tumors Pipeline analysis report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Unveil the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Gastrointestinal Stromal Tumors Market Drivers and Barriers

Scope of the Gastrointestinal Stromal Tumors Pipeline Analysis Report

  • Coverage- Global
  • Gastrointestinal Stromal Tumors Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
  • Gastrointestinal Stromal Tumors Therapies- Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.
  • Gastrointestinal Stromal Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Gastrointestinal Stromal Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Gastrointestinal Stromal Tumors Therapies and clinical trials. Download DelveInsight’s in-depth Gastrointestinal Stromal Tumor Pipeline Analysis Report today! @ Gastrointestinal Stromal Tumors Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Gastrointestinal Stromal Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Famitinib: Jiangsu Hengrui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nilotinib: Novartis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. DS 6157: Daiichi Sankyo Company
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Gastrointestinal Stromal Tumors Key Companies
  18. Gastrointestinal Stromal Tumors Key Products
  19. Gastrointestinal Stromal Tumors- Unmet Needs
  20. Gastrointestinal Stromal Tumors- Market Drivers and Barriers
  21. Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
  22. Gastrointestinal Stromal Tumors Analyst Views
  23. Gastrointestinal Stromal Tumors Key Companies
  24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastrointestinal Stromal Tumor Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

NASH Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight’s comprehensive report today! @ NASH Pipeline Outlook

Key Takeaways from the NASH Pipeline Report

  • In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
  • In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH).
  • DelveInsight’s NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment.
  • The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
  • Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.

Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs

NASH Emerging Drugs Profile

  • Lanifibranor: Inventiva Pharma

Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH.

  • MSDC-0602K: Cirius Therapeutics

MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH.

  • TERN-501: Terns Pharmaceuticals

TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH.

  • HTD 1801: HighTide Biopharma

The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).

The NASH Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment.
  • NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market

Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight’s detailed report now! @ New NASH Drugs

NASH Companies

Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.

Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

NASH Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight’s expert analysis @ NASH Market Drivers and Barriers

Scope of the NASH Pipeline Report

  • Coverage- Global
  • NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others.
  • NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others.
  • NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Nonalcoholic Steatohepatitis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lanifibranor: Inventiva Pharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. TERN-501: Terns Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. LY3849891: Eli Lilly and Company
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Nonalcoholic Steatohepatitis Key Companies
  21. Nonalcoholic Steatohepatitis Key Products
  22. Nonalcoholic Steatohepatitis- Unmet Needs
  23. Nonalcoholic Steatohepatitis- Market Drivers and Barriers
  24. Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
  25. Nonalcoholic Steatohepatitis Analyst Views
  26. Nonalcoholic Steatohepatitis Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NASH Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retinitis Pigmentosa Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Retinitis Pigmentosa Pipeline Insight 2025” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the Retinitis Pigmentosa pipeline drugs assessment profiles, including clinical and nonclinical stage products. It also covers the Retinitis Pigmentosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Retinitis Pigmentosa Pipeline. Dive into DelveInsight’s comprehensive report today! @ Retinitis Pigmentosa Pipeline Outlook

Key Takeaways from the Retinitis Pigmentosa Pipeline Drugs Assessment Report

  • In May 2025, Neurotech Pharmaceuticals announced a study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II & III, and Choroideremia. This research is being done because there are no effective therapies for people with these retinal degenerations. They are genetic disorders that affect one’s ability to see at night, and later cause tunnel vision and loss of central vision. Retinal degenerations affect the retina, a light sensitive layer of cells in the back of the eye. Slowly over time, these cells die and cause permanent loss of vision.
  • In May 2025, Beacon Therapeutics conducted a study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
  • In May 2025, AAVantgarde Bio Srl organized 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
  • DelveInsight’s Retinitis Pigmentosa Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Retinitis Pigmentosa treatment.
  • The leading Retinitis Pigmentosa Companies such as MeiraGTx, Aldeyra Therapeutics, Inc., SparingVision, Frontera Therapeutics, ProQR Therapeutics, Bionic Sight, RetroSense Therapeutics, Dompe Farmaceutici, Endogena Therapeutics, Nacuity Pharmaceuticals, Kiora Pharmaceuticals, jCyte, Ocugen, Neurotech USA, Nanoscope Therapeutics and others.
  • Promising Retinitis Pigmentosa Pipeline Therapies such as Setmelanotide, PBI-4050, OpCT-001, QR-421a, NPI-001, QR-1123, AAVB-081 and others.

Stay ahead with the most recent pipeline outlook for Retinitis Pigmentosa. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Retinitis Pigmentosa Treatment Drugs

Retinitis Pigmentosa Emerging Drugs Profile

  • Botaretigene sparoparvovec : MeiraGTx

Botaretigene sparoparvovec (bota-vec) is designed to treat the most common form of X-linked retinitis pigmentosa (XLRP) caused by mutations in the eye-specific form of the RPGR gene called RPGR open reading frame 15 (RPGR ORF15). Both rods and cones photoreceptors require RPGR ORF15 to function. AAV-RPGR has received Fast Track and Orphan Drug designations from the FDA, as well as PRIME, ATMP and Orphan Medicinal Product designations from the EMA. Currently, the drug is in Phase III stage of its development for the treatment of renitis pigmentosa.

  • ADX-2191: Aldeyra Therapeutics, Inc.

ADX-2191 is a novel drug candidate being developed by Aldeyra Therapeutics, Inc. The drug candidate is tetrahydrofolate dehydrogenase inhibitors and thymidylate synthase inhibitors. ADX-2191 received orphan drug designation in 2018. Currently, the drug is in Phase II stage of its development for the treatment of renitis pigmentosa.

  • SPVN-06 : SparingVision

SPVN06, is a novel product candidate that acts independently of the causative gene mutation. SPVN06 counteracts the degeneration of cone photoreceptors by restoring RdCVF, a neurotrophic factor naturally produced by functioning rods in the retina; and by promoting RdCVFL, a potent antioxidant which protects cones against oxidative stress. The DNA of the two distinct isoforms (RdCVF and RdCVFL) of the NXNL1 gene are supplied via an Adeno-associated virus (AAV), a viral vector classically used in gene therapy. SPVN06 is delivered via the subretinal route to the cones and retinal pigmented epithelium (RPE). Upon delivery of SPVN06, the transgenes are mainly expressed in the RPE cells for RdCVF and in the cones for RdCVFL. SPVN06 is expected to provide a long-lasting neuroprotective effect to prevent the progression of RP in patients with moderate to severe pathology. Currently, the drug is in Phase I/II stage of its development for the treatment of renitis pigmentosa.

  • FT-002: Frontera Therapeutics

FT-002 is a recombinant adeno-associated virus gene therapy drug intended to treat patients with X-linked retinitis pigmentosa (XLRP) caused by RPGR gene mutation. There is no treatment for this disease globally. FT-002 is an intraocular injection of recombinant AAV virus carrying the gene that expresses active functional proteins and repairs damaged retinal cell structure and function. One injection can effectively delay disease progression or restore the patient’s visual function. FT-002 is the first AAV gene therapy drug to be tested in XLRP patients in China and is also a potential first-in-class drug. Currently, the drug is in Phase I/II stage of its development for the treatment of Renitis Pigmentosa.

The Retinitis Pigmentosa Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Retinitis Pigmentosa with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinitis Pigmentosa Treatment.
  • Retinitis Pigmentosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Retinitis Pigmentosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinitis Pigmentosa market

Explore groundbreaking therapies and clinical trials in the Retinitis Pigmentosa Pipeline. Access DelveInsight’s detailed report now! @ New Retinitis Pigmentosa Drugs

Retinitis Pigmentosa Companies

MeiraGTx, Aldeyra Therapeutics, Inc., SparingVision, Frontera Therapeutics, ProQR Therapeutics, Bionic Sight, RetroSense Therapeutics, Dompe Farmaceutici, Endogena Therapeutics, Nacuity Pharmaceuticals, Kiora Pharmaceuticals, jCyte, Ocugen, Neurotech USA, Nanoscope Therapeutics and others.

Retinitis pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Retinitis Pigmentosa Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Retinitis Pigmentosa Treatment. Learn about new Retinitis Pigmentosa Pipeline Drugs Assessment Developments, and key companies with DelveInsight’s expert analysis @ Retinitis Pigmentosa Market Drivers and Barriers

Scope of the Retinitis Pigmentosa Pipeline Report

  • Coverage- Global
  • Retinitis Pigmentosa Companies- MeiraGTx, Aldeyra Therapeutics, Inc., SparingVision, Frontera Therapeutics, ProQR Therapeutics, Bionic Sight, RetroSense Therapeutics, Dompe Farmaceutici, Endogena Therapeutics, Nacuity Pharmaceuticals, Kiora Pharmaceuticals, jCyte, Ocugen, Neurotech USA, Nanoscope Therapeutics and others.
  • Retinitis Pigmentosa Pipeline Therapies- Setmelanotide, PBI-4050, OpCT-001, QR-421a, NPI-001, QR-1123, AAVB-081 and others.
  • Retinitis Pigmentosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Retinitis Pigmentosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Retinitis Pigmentosa Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Retinitis Pigmentosa Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Retinitis Pigmentosa: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Retinitis Pigmentosa– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Botaretigene sparoparvovec : MeiraGTx
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ADX-2191: Aldeyra Therapeutics, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SPVN-06 : SparingVision
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Retinitis Pigmentosa Key Companies
  21. Retinitis Pigmentosa Key Products
  22. Retinitis Pigmentosa- Unmet Needs
  23. Retinitis Pigmentosa- Market Drivers and Barriers
  24. Retinitis Pigmentosa- Future Perspectives and Conclusion
  25. Retinitis Pigmentosa Analyst Views
  26. Retinitis Pigmentosa Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Retinitis Pigmentosa Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma Marketed and Pipeline Drugs profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Soft Tissue Sarcoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Soft Tissue Sarcoma Pipeline Outlook

Key Takeaways from the Soft Tissue Sarcoma Marketed and Pipeline Drugs Report

  • In May 2025, Adcendo ApS announced a Phase 1/2 study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma.
  • In May 2025, ImmunoGenesis conducted a study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma. TH-302 is activated at lower oxygen concentrations than other bioreductive prodrugs (Duan 2008) and tirapazamine, a hypoxic cytotoxin that has been extensively studied in both preclinical and clinical studies.
  • In May 2025, Epizyme Inc. organized a study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
  • DelveInsight’s Soft Tissue Sarcoma Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Soft Tissue Sarcoma treatment.
  • The leading Soft Tissue Sarcoma Companies such as Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
  • Promising Soft Tissue Sarcoma Pipeline Therapies such as Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others.

Stay ahead with the most recent pipeline outlook for Soft Tissue Sarcoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Soft Tissue Sarcoma Treatment Drugs

Soft Tissue Sarcoma Emerging Drugs Profile

  • Fibronum + Doxorubicin: Philogen S.p.A.

Fibromun (L19TNF) is a fully-human immunomodulatory product consisting of the L19 antibody and TNF (a strong pro-inflammatory cytokine). (Recombinant TNF has so far been approved only for certain clinical applications.) The fusion of TNF to the L19 antibody specific to the EDB domain of fibronectin results in a tumor-targeted product, which selectively localizes at the site of disease, while sparing healthy organs. Fibromun has shown potent anti-tumor activity, both as single agent and in combination with other drugs, in several immunocompetent preclinical models inducing in most cases long-lasting complete responses. Currently, the drug is in Phase III stage of its development for the treatment of Soft Tissue Sarcoma.

  • Chiauranib: Chipscreen Biosciences, Ltd

Chiauranib, a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance. Chiauranib exerts a comprehensive anti-tumor effect by a triple-pathway mechanism that simultaneously inhibits tumor angiogenesis, prevents tumor cell mitosis, and modulates the tumor microenvironment. With a favorable safety profile, Chiauranib has outperformed drugs with a similar mechanism in its pharmacodynamic activity in animal studies.Currently, the drug is in Phase II stage of its development for the treatment of Soft Tissue Sarcoma.

  • LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited

Exlinkibart (LVGN6051) is a Anti-CD137/4-1BB agonistic monoclonal antibody and xLinkAb conditional 4-1BB agonistic monoclonal antibody with selective Fcγ-receptor IIB binding for targeted immune activation in the tumor microenvironment. LVGN6051 has achieved RP2D of 4 mg/kg Q3W, showing desirable PK and PD properties, acceptable safety profile and durable objective responses in heavily pre-treated patients with various solid tumors. Upon administration, anti-CD137 agonistic antibody LVGN6051 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. Registration clinical trials of exlinkibart in melanoma, sarcoma and head and neck cancers are planned. Currently, the drug is in Phase I/II stage of its development for the treatment of Soft Tissue Sarcoma.

The Soft Tissue Sarcoma Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
  • Soft Tissue Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market

Explore groundbreaking therapies and clinical trials in the Soft Tissue Sarcoma Pipeline. Access DelveInsight’s detailed report now! @ New Soft Tissue Sarcoma Drugs

Soft Tissue Sarcoma Companies

Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.

Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

Soft Tissue Sarcoma Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Unveil the future of Bronchiectasis Treatment. Learn about new Soft Tissue Sarcoma Marketed and Drugs Developments, and key companies with DelveInsight’s expert analysis @ Bronchiectasis Market Drivers and Barriers

Scope of the Soft Tissue Sarcoma Pipeline Report

  • Coverage- Global
  • Soft Tissue Sarcoma Companies- Philogen S.p.A., Chipscreen Biosciences, Ltd, Lyvgen Biopharma Holdings Limited, Advenchen Laboratories, LLC, OncoTherapy Science, Inc, Philogen, Washington University School of Medicine, Sun Yat-sen University, QBiotics Group Limited, Thermosome GmbH, Intensity Therapeutics, Inc., Centre Leon Berard, Institut Claudius Regaud, Base Therapeutics and others.
  • Soft Tissue Sarcoma Pipeline Therapies- Bevacizumab [Avastin], MGCD516, Pazopanib Hydrochloride, Liposomal Vincristine, AdAPT-001, Rubitecan, Ridaforolimus, OMBRABULIN (AVE8062), and others.
  • Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Soft Tissue Sarcoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Soft Tissue Sarcoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Soft Tissue Sarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Fibronum + Doxorubicin: Philogen S.p.A.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Chiauranib: Chipscreen Biosciences, Ltd
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. LVGN6051 and Anlotinib: Lyvgen Biopharma Holdings Limited
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Drug Name: Company Name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Soft Tissue Sarcoma Key Companies
  24. Soft Tissue Sarcoma Key Products
  25. Soft Tissue Sarcoma- Unmet Needs
  26. Soft Tissue Sarcoma- Market Drivers and Barriers
  27. Soft Tissue Sarcoma- Future Perspectives and Conclusion
  28. Soft Tissue Sarcoma Analyst Views
  29. Soft Tissue Sarcoma Key Companies
  30. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight